These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 35152989)

  • 21. Therapeutic potential of CRISPR/CAS9 genome modification in T cell-based immunotherapy of cancer.
    Kavousinia P; Ahmadi MH; Sadeghian H; Hosseini Bafghi M
    Cytotherapy; 2024 May; 26(5):436-443. PubMed ID: 38466263
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combining different CRISPR nucleases for simultaneous knock-in and base editing prevents translocations in multiplex-edited CAR T cells.
    Glaser V; Flugel C; Kath J; Du W; Drosdek V; Franke C; Stein M; Pruß A; Schmueck-Henneresse M; Volk HD; Reinke P; Wagner DL
    Genome Biol; 2023 Apr; 24(1):89. PubMed ID: 37095570
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Erratic journey of CRISPR/Cas9 in oncology from bench-work to successful-clinical therapy.
    Sarkar E; Khan A
    Cancer Treat Res Commun; 2021; 27():100289. PubMed ID: 33667951
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
    Morgan MA; Büning H; Sauer M; Schambach A
    Front Immunol; 2020; 11():1965. PubMed ID: 32903482
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR/Cas9 gene editing technology.
    Tao R; Han X; Bai X; Yu J; Ma Y; Chen W; Zhang D; Li Z
    Front Immunol; 2024; 15():1354825. PubMed ID: 38449862
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Engineering strategies to safely drive CAR T-cells into the future.
    Rossi M; Breman E
    Front Immunol; 2024; 15():1411393. PubMed ID: 38962002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CRISPR/Cas9-mediated TGFβRII disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells in vitro.
    Alishah K; Birtel M; Masoumi E; Jafarzadeh L; Mirzaee HR; Hadjati J; Voss RH; Diken M; Asad S
    J Transl Med; 2021 Nov; 19(1):482. PubMed ID: 34838059
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies.
    Razeghian E; Nasution MKM; Rahman HS; Gardanova ZR; Abdelbasset WK; Aravindhan S; Bokov DO; Suksatan W; Nakhaei P; Shariatzadeh S; Marofi F; Yazdanifar M; Shamlou S; Motavalli R; Khiavi FM
    Stem Cell Res Ther; 2021 Jul; 12(1):428. PubMed ID: 34321099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genome Editing in CAR-T Cells Using CRISPR/Cas9 Technology.
    Andreu-Saumell I; Rodriguez-Garcia A; Guedan S
    Methods Mol Biol; 2024; 2748():151-165. PubMed ID: 38070114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CRISPR/Cas systems to overcome challenges in developing the next generation of T cells for cancer therapy.
    Huang D; Miller M; Ashok B; Jain S; Peppas NA
    Adv Drug Deliv Rev; 2020; 158():17-35. PubMed ID: 32707148
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protocol for Efficient Generation of Chimeric Antigen Receptor T Cells with Multiplexed Gene Silencing by Epigenome Editing.
    Azcona MSR; Mussolino C
    Methods Mol Biol; 2024; 2842():209-223. PubMed ID: 39012598
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Strengthening the CAR-T cell therapeutic application using CRISPR/Cas9 technology.
    Sadeqi Nezhad M; Yazdanifar M; Abdollahpour-Alitappeh M; Sattari A; Seifalian A; Bagheri N
    Biotechnol Bioeng; 2021 Oct; 118(10):3691-3705. PubMed ID: 34241908
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Better living through chemistry: CRISPR/Cas engineered T cells for cancer immunotherapy.
    Wellhausen N; Agarwal S; Rommel PC; Gill SI; June CH
    Curr Opin Immunol; 2022 Feb; 74():76-84. PubMed ID: 34798542
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells.
    Sterner RM; Cox MJ; Sakemura R; Kenderian SS
    J Vis Exp; 2019 Jul; (149):. PubMed ID: 31380838
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacological interventions enhance virus-free generation of
    Kath J; Du W; Pruene A; Braun T; Thommandru B; Turk R; Sturgeon ML; Kurgan GL; Amini L; Stein M; Zittel T; Martini S; Ostendorf L; Wilhelm A; Akyüz L; Rehm A; Höpken UE; Pruß A; Künkele A; Jacobi AM; Volk HD; Schmueck-Henneresse M; Stripecke R; Reinke P; Wagner DL
    Mol Ther Methods Clin Dev; 2022 Jun; 25():311-330. PubMed ID: 35573047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An "off-the-shelf" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies.
    Cooper ML; Choi J; Staser K; Ritchey JK; Devenport JM; Eckardt K; Rettig MP; Wang B; Eissenberg LG; Ghobadi A; Gehrs LN; Prior JL; Achilefu S; Miller CA; Fronick CC; O'Neal J; Gao F; Weinstock DM; Gutierrez A; Fulton RS; DiPersio JF
    Leukemia; 2018 Sep; 32(9):1970-1983. PubMed ID: 29483708
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CRISPR-Cpf1-mediated genome editing and gene regulation in human cells.
    Li T; Zhu L; Xiao B; Gong Z; Liao Q; Guo J
    Biotechnol Adv; 2019; 37(1):21-27. PubMed ID: 30399413
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elucidation of CRISPR-Cas9 application in novel cellular immunotherapy.
    Quazi S
    Mol Biol Rep; 2022 Jul; 49(7):7069-7077. PubMed ID: 35122203
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Review: Sustainable Clinical Development of CAR-T Cells - Switching From Viral Transduction Towards CRISPR-Cas Gene Editing.
    Wagner DL; Koehl U; Chmielewski M; Scheid C; Stripecke R
    Front Immunol; 2022; 13():865424. PubMed ID: 35784280
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9.
    Ren J; Zhao Y
    Protein Cell; 2017 Sep; 8(9):634-643. PubMed ID: 28434148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.